C840H1330N222O242S8 Description Lenograstim is a recombinant granulocyte colonystimulating factor which functions as an immuno stimulator Indication The drug is used to reduce the risk of lifethreatening infection in patients with neutropenia particularly after cytotoxic ch ID: 935021
Download Presentation The PPT/PDF document "Lenograstim Chemical Formula :" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Lenograstim
Chemical Formula :
C840-H1330-N222-O242-S8
Slide2Description
:
Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as an
immuno stimulator
.
Slide3Indication
:
The drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. GRANOCYTE ( Lenograstim) is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. GRANOCYTE is also indicated to
mobilise
peripheral blood progenitor cells (PBPCs) with GRANOCYTE alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. GRANOCYTE is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome)
.
Slide4Mechanism of Action
:
Lenograstim is the glycosylated recombinant form of human granulocyte colony stimulating factor. Lenograstim accelerates neutrophil recovery significantly after chemotherapy, with beneficial effects on clinical end-points such as incidence of laboratory-confirmed infection and length of hospital stay. Chemotherapy dose intensity has also been increased in patients receiving
lenograstim
, notably those with breast or small cell lung cancer, although improvements in
tumour
response and survival have not been demonstrated. Lenograstim also assists neutrophil recovery in patients undergoing bone marrow transplantation, and stimulates the production of peripheral blood stem cells (PBSCs) for autologous transfusion after aggressive chemotherapy.
Categories
:
Antineoplastic and Immunomodulating Agents
Slide5Brands
:
Granocyte
Description
:
Granocyte
injection contains the active ingredient
lenograstim
, which is a type of medicine called a recombinant human granulocyte-colony stimulating factor (G-CSF
).
Slide6Route
of administration :
Subcutaneous or Intravenous
Contraindications
:
People with malignancies affecting myeloid
cell.
Side Effects:
Decrease in the number of platelets in the blood (thrombocytopenia), Headache, Feeling weak, Bone pain, Back pain, Elevated levels of liver
enzymes.
Slide7References
:
http://www.netdoctor.co.uk/medicines/cancer/a6818/granocyte-lenograstim/
https
://
www.drugs.com/international/lenograstim.html